Breast (Oct 2022)
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
- Sung Hoon Sim,
- Jeong Eun Kim,
- Min Hwan Kim,
- Yeon Hee Park,
- Jee Hyun Kim,
- Koung Jin Suh,
- Su-Jin Koh,
- Kyong Hwa Park,
- Myoung Joo Kang,
- Mi Sun Ahn,
- Kyoung Eun Lee,
- Hee-Jun Kim,
- Hee Kyung Ahn,
- Han Jo Kim,
- Keon Uk Park,
- Jae Ho Byun,
- Jin Hyun Park,
- Gyeong-Won Lee,
- Keun Seok Lee,
- Joohyuk Sohn,
- Kyung Hae Jung,
- In Hae Park
Affiliations
- Sung Hoon Sim
- Center for Breast Cancer, National Cancer Center, Goyang, South Korea
- Jeong Eun Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
- Min Hwan Kim
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
- Yeon Hee Park
- Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Jee Hyun Kim
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea
- Koung Jin Suh
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea
- Su-Jin Koh
- Department of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, South Korea
- Kyong Hwa Park
- Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Anam Hospital, Seoul, South Korea
- Myoung Joo Kang
- Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea
- Mi Sun Ahn
- Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, South Korea
- Kyoung Eun Lee
- Department of Hematology and Oncology, Ewha Womans University Hospital, Seoul, South Korea
- Hee-Jun Kim
- Division of Hematology/Medical Oncology, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, South Korea
- Hee Kyung Ahn
- Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea
- Han Jo Kim
- Division of Oncology and Hematology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea
- Keon Uk Park
- Division of Hematology/Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, South Korea
- Jae Ho Byun
- Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
- Jin Hyun Park
- Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea
- Gyeong-Won Lee
- Division of Hematology and Oncology Department of Internal Medicine Gyeongsang National University College of Medicine, Jinju, South Korea
- Keun Seok Lee
- Center for Breast Cancer, National Cancer Center, Goyang, South Korea
- Joohyuk Sohn
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
- Kyung Hae Jung
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
- In Hae Park
- Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Guro Hospital, Seoul, South Korea; Corresponding author. Korea University, College of Medicine, Department of Hemato-Oncology, Guro Hospital.
- Journal volume & issue
-
Vol. 65
pp. 172 – 178
Abstract
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
